LittleBuford
Well-Known Member
I'm not sure why we're not understanding each other, but my posts have been pretty clear in content and intent. I'm moving on from this exchange.My comments were specifically on the article you posted which was about the UK.
The AstraZenneca vaccine was tested in a clinical trial in South Africa where the vast majority of cases came from the S African variant and it showed very poor efficacy. JnJ was also tested in S Africa in a clinical trial and showed a much higher efficacy than AstraZenneca that was still above the threshold that was set by the FDA. That‘s not to say that JnJ won’t also eventually need a booster but it’s definitely more pressing for AstraZenneca.
Pfizer and Moderna were not tested in real life in S Africa with a trial. We know from the study you posted that they produce less antibodies vs that variant but that’s in a lab and the researchers acknowledged the sample size was small and that it’s not fully known how the Pfizer and Moderna vaccines will work in real life against the South African variant. There are factors beyond antibodies that impact efficacy. Both Pfizer and Moderna are looking into creating boosters for that variant if it becomes a problem here or anywhere else and that’s the beauty of the mRNA vaccines, easily apadtable. The S African government has switched their vaccination effort to the Pfizer vaccine from AstraZenneca so we should get a lot of real life data relatively soon on how the vaccine works there vs the variant.
So far in both the UK and the US the number of cases with the S African variant are extremely low. It’s something to monitor for sure, but not a direct threat to the current vaccine effort in either place. Probably a good reason to limit international travel a bit longer though.